2026-08-29T12:39:10Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/187932024-09-21T19:05:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16970
Repisalud author Fernández-Montes, Ana author Alcaide, Julia author Alsina, María author Custodio, Ana Belén author Franco, Lourdes Fernández author Gallego Plazas, Javier author Gómez-Martín, Carlos author Richart, Paula author Rivera, Fernando author Martin-Richard, Marta 2024-02-27T15:16:12Z 2024-02-27T15:16:12Z 2022-03-26 10.1007/s12094-022-02801-2 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/21075 35347573 http://hdl.handle.net/20.500.12105/18793 Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care. eng Diagnosis Esophageal cancer Treatment SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). research article